- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Serum Institute validates getting Rs 1732 crore from Govt for 11 crore Covishield doses
New Delhi: Serum Institute of India (SII) on Monday endorsed the government statement that 100 per cent advance of Rs 1,732.50 crore has been released to the company on April 28 for 11 crore doses of the Covishield vaccine for May, June and July. "We endorse this statement, & the authenticity of the information.
We have been working closely with the Government of India for the past year & thank it for its support. We remain committed to ramping up our vaccine production to save every life we can," SII said on Twitter.
The company's response came after the Health Ministry in a statement refuted allegations that it has not placed any fresh orders for the Covishield vaccine with SII.
The Health Ministry earlier said that it has paid the entire advance of Rs 1,732.50 crore to SII for 11 crore doses of Covishield vaccine for three months -- May, June and July.
The amount, which after TDS was Rs 1,699.50 crore, was received by the SII on April 28 itself, it said.
As on date, against the last order of 10 crore doses for supplies of Covishield vaccine, 8.744 crore doses have been delivered till May 3, the ministry said, adding, media reports alleging that the Centre has not placed any fresh order for COVID-19 vaccines are "incorrect and not based on facts".
Additionally, 100 per cent advance of Rs 787.50 crore (after TDS Rs 772.50 crore) was released on April 28 to Bharat Biotech India Ltd (BBIL) for five crore Covaxin doses during May, June and July. The amount was received by them on April 28.
As on date against the last order of two crore doses for supplies of Covaxin vaccine, 0.8813 crore doses have been delivered till May 3, the ministry said.
"Hence, to say that fresh orders have not been placed by the Government of India is not correct," it said.
As of May 2, the Centre has provided more 16.54 crore vaccine doses to states and union territories free of cost. More than 78 lakh doses are still available with them to be administered, the ministry said.
"More than 56 lakh doses, in addition, will be received by states and UTs in the next three days," it stated.
Under the Liberalised Pricing and Accelerated National COVID-19 Vaccination Strategy, the Government of India would continue to procure its share of 50 per cent of the monthly Central Drugs Laboratory (CDL) cleared vaccines and would continue to make it available to the state governments totally free of cost as was being done earlier, the ministry stated.
serum institute of indiaserum institute of india newscovishieldcoronaviruscovid-19coronavirus vaccine
Source : PTIRuchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story